China's COVID-19 vaccine candidate shows promise in human trials, CNBG says - (Fidelity via NewsPoints Desk)

  • China National Biotec Group announced its COVID-19 vaccine candidate has triggered antibodies in clinical trials and the company plans late-stage clinical trials in foreign countries, as reported in Fidelity.

  • According to the preliminary data from 1120 healthy participants, the vaccine, developed by a Wuhan-based research institute affiliated to CNBG's parent company Sinopharm, was found to have induced high-level antibodies in all inoculated people without adverse effects.

  • CNBG said it is proactively seeking opportunities for Phase 3 trials overseas, adding that it has "secured cooperative intent with companies and institutes in many countries."

  • Meanwhile, Sinovac Biotech released recently positive preliminary clinical trial results for its potential vaccine candidate, which is expected to be tested in a Phase III trial in Brazil.

To read more NewsPoints articles, click here.